Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 419-480-1 | CAS number: -
Toxicological information
Skin sensitisation
Currently viewing:
Administrative data
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 15 March 1994 to 08 April 1994
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study conducted to EU and OECD guidelines in compliance with GLP.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 994
- Report date:
- 1994
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.6 (Skin Sensitisation)
- Version / remarks:
- Guideline 84/449
- Deviations:
- no
- GLP compliance:
- yes
- Type of study:
- guinea pig maximisation test
Test material
- Reference substance name:
- -
- EC Number:
- 419-480-1
- EC Name:
- -
- IUPAC Name:
- Reaction mass of tetrasodium 2-((1-(3-(6-fluoro-(4-((N-(2-(2-sulfatoethanesulfonyl)ethyl)-N-phenyl)amino)-1,3,5-triazin-2-ylamino)-2-hydroxy-5-sulfonatophenylazo)-1-phenylmethyl)azo)-4-sulfonatobenzoate cuprate (4-) and trisodium 2-((1-(3-((4-(N-(2-ethenesulfonylethyl)-N-phenyl)amino)-6-fluoro-1,3,5-triazin-2-ylamino)-2-hydroxy-5-sulfonatophenylazo)-1-phenylmethyl)azo)-4-sulfonatobenzoate cuprate (4-)
- Test material form:
- solid: particulate/powder
- Remarks:
- migrated information: powder
- Details on test material:
- - Name of test material (as cited in study report): Reactive Blue FC 75311
Constituent 1
In vivo test system
Test animals
- Species:
- guinea pig
- Strain:
- Dunkin-Hartley
- Sex:
- male/female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Harlan Winkelmann GmbH
- Age at study initiation: 5 to 7 Weeks
- Weight at study initiation: Mean 331g (298 to 360g)
- Housing: 2 -3 animals per cage
- Diet (e.g. ad libitum): Altromin 3020, ad libitum
- Water (e.g. ad libitum): Tap water, ad libitum
- Acclimation period: at least 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21
- Humidity (%): 40 - 70
- Air changes (per hr): 12 - 15 times per hour
- Photoperiod (hrs dark / hrs light): 12 hours, artificial illumination from 6am to 6 pm
Study design: in vivo (non-LLNA)
Inductionopen allclose all
- Route:
- intradermal
- Vehicle:
- physiological saline
- Concentration / amount:
- Intradermal induction: 5% (=20 mg test compound/animal)
Topical induction: 50% (=250 mg test compound/animal)
Challenge: 50% (=250 mg test compound/animal) and 25% (=125 mg test compound/animal)
Challengeopen allclose all
- Route:
- epicutaneous, occlusive
- Vehicle:
- physiological saline
- Concentration / amount:
- Intradermal induction: 5% (=20 mg test compound/animal)
Topical induction: 50% (=250 mg test compound/animal)
Challenge: 50% (=250 mg test compound/animal) and 25% (=125 mg test compound/animal)
- No. of animals per dose:
- One test substance group consisting of 20 experimental animals (No. 21 to 40) and two control groups consisting of 10 animals each (No. 1 to 10 and 11 to 20)
- Details on study design:
- Intradermal Induction
One day prior to application the skin on the dorsum and the flanks was shorn. Starting behind the nucha,three intradermal injections were administered on each side of and parallel to the spinal column.
The application volume per injection site was 0.1 ml, The animals of the three groups were treated as follows:
a) Test substance group
1. Injection site pair (cranial)
Freund's complete adjuvant (Difco Lab.) 1:1 diluted with physiological saline solution (sterile).
2. Injection site pair (medial)
Reactive Blue FC 75311 5%, formulated with physiological saline solution (sterile).
3. Injection site pair (caudal)
Reactive Blue FC 75311 5%, formulated in physiological saline solution and Freund's complete adjuvant in equal proportions.
b) Control groups
The animals of the control groups were treated like the animals of the test substance group, the formulation for the injection site pairs 2 and 3, however, contained no test compound but a corresponding amount of sterile physiological saline solution.
Topical Induction
One week after intradermal induction topical induction took place. On the eve, the areas to be treated were shorn, and a 10% preparation of sodium lauryl sulphate in Vaseline was spread on these areas. Hypoallergenic patches {2x4 cm) were applied between or on the injection sites; they were covered with aluminum foil and kept in place on the skin with Fermoflex adhesive tape (Transatlantic GmbH, Schwarzenbach).
The hypoallergenic patches were treated as follows:
a) Test substance group: 0.5 ml Reactive Blue 75311 50%
b) Control group: 0.5 ml physiological saline solution (sterile)
At the end of the 48-hour exposure period the substance residues were removed with tap water.
Topical Challenge of Sensitization
The topical challenge took place 3 weeks after intradermal induction. Meanwhile, the test compound concentration for challenge had been determined in a range-finding test on 5 guinea pigs treated like control animals during inductions.
One day prior to the treatment the animals were shorn on the dorsum and the flanks. For challenge a hypoallergenic patch saturated with 50% and 25% test compound formulation was placed on the left flank of the animals of the test substance group and the ist control group. The patch was fixed for 24 hours on the skin with Fermoflex adhesive tape. The patches were applied in both concentrations cranially or caudally - alternately from animal to animal. On the right flank two control patches were fixed, saturated only with sterile physiological saline solution.
The application volume was 0.5 ml in each case.
At the end of the exposure period, substance residues were removed with tap water. 21 hours later the skin of the animals was depilated in the region of the treated areas. Pilca cream (depilation cream for humans, containing salts of the thioglycolic acid; manufactured by Schwarzkopf GmbH, Hamburg) was used for that purpose. - Challenge controls:
- Control groups
The animals of the control groups were treated like the animals of the test substance group, the formulation for the injection site pairs 2 and 3, however, contained no test compound but a corresponding amount of sterile physiological saline solution. - Positive control substance(s):
- yes
- Remarks:
- 2-mercaptobenzothiazole. See below under free text
Study design: in vivo (LLNA)
- Vehicle:
- other: Not applicable
- Statistics:
- To assess if and to what extent sensitization occurred, the number of animals of the test substance group and the control group with a skin irritant reaction and the severity of the reactions were established and a comparison was made. The criterion for sensitization was whether the occurrence of skin irritant reactions was more frequent and severe for the animals of the test substance group than for the control group.
Results and discussion
- Positive control results:
- As above.
In vivo (non-LLNA)
Resultsopen allclose all
- Reading:
- 1st reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 25%
- No. with + reactions:
- 1
- Total no. in group:
- 20
- Clinical observations:
- Test substance patch, skin reddening.
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 48.0. Group: test group. Dose level: 25%. No with. + reactions: 1.0. Total no. in groups: 20.0. Clinical observations: Test substance patch, skin reddening..
- Reading:
- 2nd reading
- Hours after challenge:
- 72
- Group:
- test chemical
- Dose level:
- 25%
- No. with + reactions:
- 2
- Total no. in group:
- 20
- Clinical observations:
- Test substance patch, skin reddening.
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 72.0. Group: test group. Dose level: 25%. No with. + reactions: 2.0. Total no. in groups: 20.0. Clinical observations: Test substance patch, skin reddening..
- Reading:
- 1st reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 25%
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- Control patch, skin reddening
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 48.0. Group: test group. Dose level: 25%. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: Control patch, skin reddening.
- Reading:
- 2nd reading
- Hours after challenge:
- 72
- Group:
- test chemical
- Dose level:
- 25%
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- Control patch, skin reddening
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 72.0. Group: test group. Dose level: 25%. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: Control patch, skin reddening.
- Reading:
- 1st reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- 25%
- No. with + reactions:
- 1
- Total no. in group:
- 10
- Clinical observations:
- Test substance patch, skin reddening
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 48.0. Group: negative control. Dose level: 25%. No with. + reactions: 1.0. Total no. in groups: 10.0. Clinical observations: Test substance patch, skin reddening.
- Reading:
- 2nd reading
- Hours after challenge:
- 72
- Group:
- negative control
- Dose level:
- 25%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- Test substance patch, skin reddening
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 72.0. Group: negative control. Dose level: 25%. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: Test substance patch, skin reddening.
- Reading:
- 1st reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- 25%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- Control patch, skin reddening
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 48.0. Group: negative control. Dose level: 25%. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: Control patch, skin reddening.
- Reading:
- 2nd reading
- Hours after challenge:
- 72
- Group:
- negative control
- Dose level:
- 25%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- Control patch, skin reddening
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 72.0. Group: negative control. Dose level: 25%. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: Control patch, skin reddening.
- Reading:
- 1st reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 50%
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- Test substance patch, skin reddening
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 48.0. Group: test group. Dose level: 50%. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: Test substance patch, skin reddening.
- Reading:
- 2nd reading
- Hours after challenge:
- 72
- Group:
- test chemical
- Dose level:
- 50%
- No. with + reactions:
- 1
- Total no. in group:
- 20
- Clinical observations:
- Test substance patch, skin reddening
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 72.0. Group: test group. Dose level: 50%. No with. + reactions: 1.0. Total no. in groups: 20.0. Clinical observations: Test substance patch, skin reddening.
- Reading:
- 1st reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 50%
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- Control patch, skin reddening
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 48.0. Group: test group. Dose level: 50%. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: Control patch, skin reddening.
- Reading:
- 2nd reading
- Hours after challenge:
- 72
- Group:
- test chemical
- Dose level:
- 50%
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- Control patch, skin reddening
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 72.0. Group: test group. Dose level: 50%. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: Control patch, skin reddening.
- Reading:
- 1st reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- 50%
- No. with + reactions:
- 2
- Total no. in group:
- 10
- Clinical observations:
- Test substance patch, skin reddening
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 48.0. Group: negative control. Dose level: 50%. No with. + reactions: 2.0. Total no. in groups: 10.0. Clinical observations: Test substance patch, skin reddening.
- Reading:
- 2nd reading
- Hours after challenge:
- 72
- Group:
- negative control
- Dose level:
- 50%
- No. with + reactions:
- 1
- Total no. in group:
- 10
- Clinical observations:
- Test substance patch, skin reddening
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 72.0. Group: negative control. Dose level: 50%. No with. + reactions: 1.0. Total no. in groups: 10.0. Clinical observations: Test substance patch, skin reddening.
- Reading:
- 1st reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- 50%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- Control patch, skin reddening
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 48.0. Group: negative control. Dose level: 50%. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: Control patch, skin reddening.
- Reading:
- 2nd reading
- Hours after challenge:
- 72
- Group:
- negative control
- Dose level:
- 50%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- Control patch, skin reddening
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 72.0. Group: negative control. Dose level: 50%. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: Control patch, skin reddening.
In vivo (LLNA)
Resultsopen allclose all
- Parameter:
- SI
- Remarks on result:
- other: Not applicable.
- Parameter:
- other: disintegrations per minute (DPM)
- Remarks on result:
- other: Not applicable.
Any other information on results incl. tables
The incidences of skin reddenings after challenge are summarized in the following table-.
|
Test substance Group (20 animals) |
1stControl group (10 animals) |
||||||||
Test substance patch |
Control patch |
Test substance patch |
Control patch |
|||||||
Hours |
48 |
72 |
Total |
48 |
72 |
48 |
72 |
Total |
48 |
72 |
Challenge 50% |
0 |
1 |
1 |
0 |
0 |
2 |
1 |
2 |
0 |
0 |
Challenge 25% |
1 |
2 |
2 |
0 |
0 |
1 |
0 |
1 |
0 |
0 |
Applicant's summary and conclusion
- Interpretation of results:
- not sensitising
- Remarks:
- Migrated information
- Conclusions:
- The substance was found to be non-sensitising in the maximisation test.
- Executive summary:
Reactive Blue FC 75311 was evaluated for potential skin sensitizing properties in a maximisation test as described by MAGNUSSON and KLIGMANN. The test was performed on female guinea pigs.
The test compound was formulated in physiological saline solution (sterile) as a suspension.
After challenge one animal (5%) and two animals (10%) of the test substance group reacted with skin reddening to the 50% and 25% test compound formulation, respectively. In the control group two animals (20%) and one animal (10%), respectively, showed skin reactions.
Thus, under the conditions of the maximization test, the test compound has no skin sensitizing potential.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
